Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases

(2014) Fanny Leroy et al.   BMC Medical Research Methodology

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

(2014) Keith B. Hoffman et al.   DRUG SAFETY

Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

(2014) William P Kennedy et al.   ARTHRITIS RESEARCH & THERAPY

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

(2014) Gerd R Burmester et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

(2013) Pieter Dewint et al.   GUT

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia–Romagna region)

(2012) Chiara Biagi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study

(2011) Abel N Kho et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial

(2011) Patrick Kwan et al.   LANCET NEUROLOGY

PHP54 EVALUATING DIFFERENCES IN DRUG REIMBURSEMENT BETWEEN MAIL-ORDER AND COMMUNITY PHARMACY

(2011) J Visaria et al.   VALUE IN HEALTH

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

(2010) Morten L. Hansen et al.   ARCHIVES OF INTERNAL MEDICINE

Adverse drug events in the outpatient setting: an 11-year national analysis

(2010) Florence T. Bourgeois et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV

(2009) C. Daniel Mullins et al.   VALUE IN HEALTH

Incentives for orphan drug research and development in the United States

(2008) Enrique Seoane-Vazquez et al.   Orphanet Journal of Rare Diseases